Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lerapolturev + lomustine
- Development stage
- Phase 2
- Lead developer
- Istari Oncology
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intratumoral, Subcutaneous, Oral
01
Overview
Lerapolturev + lomustine is an investigational drug combination being evaluated in clinical trials for the treatment of recurrent glioblastoma. Lerapolturev (also known as PVSRIPO) is a genetically modified oncolytic poliovirus designed to induce antitumor immune response by infecting and lysing tumor cells and stimulating local immune activation. Lomustine is a small molecule chemotherapy agent from the nitrosourea class, which acts as an alkylating agent that cross-links and alkylates DNA, leading to cancer cell death. Lerapolturev is administered intratumorally via convection enhanced delivery, followed by subcutaneous injection near cervical lymph nodes, while lomustine is given orally. The combination is being studied for efficacy and safety in adults with recurrent glioblastoma after maximal safe resection, with each drug arm administered separately in the study protocol[1][3][5].
- Other names
- lerapolturevlomustinePVSRIPOCCNUchloroethylcyclohexylnitrosourea
02
Targets
DNAPVR
Beyond the preview
Go deeper on lerapolturev + lomustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lerapolturev + lomustine.